PreveCeutical Medical Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen Van Deventer
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 885 Cambie Street Vancouver BC Canada V6B 0R6
- IPO Date
- Aug 21, 2017
- Website
- preveceutical.com
- Similar Companies
- Business
- PreveCeutical Medical Inc. operates as a health sciences enterprise dedicated to pioneering innovative solutions for both preventative and restorative treatments, leveraging natural and bio-identical substances. Its robust research pipeline includes a sophisticated cannabinoid sol-gel platform designed for efficient nose-to-brain delivery, addressing various conditions such as pain, inflammation, seizure disorders, and neurological ailments. The company is also advancing peptide initiatives, notably a program focused on nature-identical peptides derived from blue scorpion venom, aimed at inhibiting cancer progression, and a non-addictive analgesic program for pain management which commenced clinical development in 2023. Furthermore, PreveCeutical is developing a dual gene therapy specifically targeting type 2 diabetes and obesity, with preclinical studies currently underway and gaining interest from major pharmaceutical entities. This metabolic and gene-based therapy research is significantly driven by its subsidiary, BioGene Therapeutics Inc., which recently launched its own dedicated website. Additionally, the company is exploring therapeutic options for individuals suffering from concussions. PreveCeutical Medical Inc. maintains its corporate headquarters in Vancouver, Canada.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
PreveCeutical Announces Extension of Non-Brokered Private Placement
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
PreveCeutical Announces Non-Brokered Private Placement
PreveCeutical Adopts Semi-Annual Financial Reporting
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement
CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement